VivoSeq
Oncology

Germ Cell Tumors

6

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Germ Cell Tumors is an early-stage landscape with 6 programs across 4 companies. The most active players are Teva, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2A

Avyxa

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01873326·92 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)